Compare SBFM & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SBFM | JAGX |
|---|---|---|
| Founded | 2006 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3M | 4.9M |
| IPO Year | 2008 | 2014 |
| Metric | SBFM | JAGX |
|---|---|---|
| Price | $1.15 | $0.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $7.00 | ★ $60.00 |
| AVG Volume (30 Days) | ★ 393.8K | 226.9K |
| Earning Date | 04-03-2026 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 82.42 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $36,305,891.00 | $11,511,000.00 |
| Revenue This Year | $40.47 | $61.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.11 | N/A |
| 52 Week Low | $0.25 | $0.22 |
| 52 Week High | $3.05 | $8.00 |
| Indicator | SBFM | JAGX |
|---|---|---|
| Relative Strength Index (RSI) | 40.08 | 17.64 |
| Support Level | $1.09 | $0.29 |
| Resistance Level | $1.29 | $0.46 |
| Average True Range (ATR) | 0.09 | 0.10 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 40.07 | 3.48 |
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.